HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 4 of 4
Hodgkin Lymphoma (NHL) (BIANCA)
This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).
Related PI: Shannon L. Maude, MD, PhD
Related Conditions: Non-Hodgkins Lymphoma, Oncology, CAR T Cell Therapy, Gene Therapy
Phase 2 trial of CART19 for Orphan Indications Of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.
Related PI: Amanda DiNofia, MD
Related Conditions: B Cells, Acute Lymphoblastic Leukemia, Oncology, CAR T Cell Therapy, Gene Therapy
Study of Efficacy and Safety of Tisagenlecleucel in Children and Young Adults with HR B-ALL that is end-consolidation MRD Positive (AALL1721/CASSIOPEIA)
The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia that remains MRD-positive after 2 cycles of chemotherapy.
Related PI: Shannon L. Maude, MD, PhD
Related Conditions: CAR T Cell Therapy, Oncology, Gene Therapy
UCART22
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").
Related PI: Stephan A. Grupp, MD, PhD
Related Conditions: Acute Lymphoblastic Leukemia, CAR T Cell Therapy, Cancer, Gene Therapy